Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768209 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment
A Phase 1 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00768209 is a Phase 1 study that has completed, run by VIVUS. The registered enrollment target is 18 participants.
The verdict
NCT00768209, a Phase 1 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is designed to determine the effects of a single dose of the study medication in subjects with and without hepatic impairment. 18 to 24 subjects will participate by having multiple blood draws taken to measure the level of study medication in their blood over time.
Interventions
- DRUG Phentermine and Topiramate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768209
The ClinicalTrials.gov registry entry for NCT00768209 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Phentermine and Topiramate is the first listed.
NCT00768209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768209 about?
NCT00768209 is a clinical study titled "A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment". This study is designed to determine the effects of a single dose of the study medication in subjects with and without hepatic impairment. 18 to 24 subjects will participate by having multiple blood draws taken to measure the level of study medication in their blood over time.
What is the current status of trial NCT00768209?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2008-10. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00768209?
The interventions under investigation include: Phentermine and Topiramate (DRUG).
Who is sponsoring clinical trial NCT00768209?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.